New Drug : Andexanet Alfa- Reversal agent for Factor X a inhibitors

NEJM- Nov 2015 – ANNEXA-A and ANNEXA-R ClinicalTrials As of now the major limiting factor with the use of novel anticoagulants is the absence of  reversal agents in case of bleeding complications. To find a solution to this problem, a new drug has been recently tested in ANNEXA-A and ANNEXA-R trials. Andexanet alfa, a new drug designed […]

MI rates with Ticagrelor (from PLATO)

This article in JACC examines the rates of MI in patients with ACS treated with ticagrelor vs clopidogrel. The rates of overall MI at 12 months: 1. Ticagrelor- 5.8% 2. Clopidogrel – 6.9% 3. Nonprocedural MI (HR: 0.86; 95% CI: 0.74 to 1.01) and MI related to percutaneous      coronary intervention or stent thrombosis tended […]

%d bloggers like this: